February 1, 2012

As part of DSN's Executive Retailer Viewpoint series, DSN sat down with Jason Reiser, VP health and wellness, ops/compliance at Sam's Club, at DSN's Industry Issues Summit to discuss how to better engage customers and the impact of the economy on business in 2012.

January 18, 2012

In an effort to tap into the minds of some of the industry's top executives, Drug Store News recently sat down and talked with some of these leaders in a multipart executive viewpoint video series.

April 22, 2015

If you were impressed by the recent switches of Nasacort Allergy 24HR, Nexium 24HR or Flonase — well-executed and model switches — well, you ain’t seen nothing yet.

March 4, 2015

Almost half of all circular ads in support of a digestive remedy promote an antacid tablet. 

March 4, 2015

There was a $1.1 billion gain in OTC sales between 2013 and 2014, according to data culled from IRI, some $500 million of which can be attributed to an increase in sales across all cough-cold/allergy/sinus products and an approximate $300 million to a rise in digestive sales.

March 4, 2015

Drug Store News has partnered with Competitive Promotion Report and IRI to create a series of exclusive reports. This edition explores cold/allergy/sinus products in both the liquid/powder and tablets/packets segments.

March 4, 2015

While the big four analgesic manufacturers — Bayer, Pfizer, McNeil and Novartis — command the lion’s share of retail ad support behind their mega analgesic brands, Prestige Brands and BedRock Brands are making headway promoting their niche pain relieving products.

February 27, 2015

Camber Pharmaceuticals' latest generic drug launch is used to treat pulmonary hypertension.

February 26, 2015

Greenstone, a subsidiary of Pfizer, announced the introduction of trandolapril/verapamil hydrochloride extended-release tablets to its line of generic pharmaceutical products. 

 

February 9, 2015

Onco360 on Monday announced that it has been selected by Pfizer as a limited-distribution pharmacy network participant for Ibrance (palbociclib), Pfizer’s recently approved product for certain breast cancers.

February 6, 2015

Prestige Brands will be resuming healthcare professional marketing programs in support of its Monistat vaginal treatments.

February 5, 2015

There is a sharp spike in cough-cold promotion across retail circulars in the back-to-school season, according to an analysis of circular retail promotions provided by ECRM, as moms prepare their families for the inevitable season of sniffles and sneezes with the coming school year.

February 5, 2015

Pfizer has entered into a definitive merger agreement to acquire Hospira.

 

January 26, 2015

NJOY announced the appointment of Paul Sturman as its new CEO and president. 

 

January 21, 2015

Boehringer Ingelheim Pharmaceuticals on Wednesday announced that its Spiriva Respimat (tiotropium bromide) inhalation spray is now available by prescription through pharmacies across the United States. 

 

January 9, 2015

Teva Pharmaceuticals on Friday announced the launch of linezolid injection, the generic equvialent to Zyvox injection from C.P. Pharmaceuticals.

January 7, 2015

Three supplement categories are really helping to drive the business today.

December 22, 2014

The Food and Drug Administration has approved Zerbaxa (ceftolozane/tazobactam), a new antibacterial drug product, to treat adults with complicated intra-abdominal infections and complicated urinary tract infections.

December 16, 2014

 Greenstone announced the launch of celecoxib — the authorized generic version of Pfizer's Celebrex — to its line of generic pharmaceuticals. 

December 16, 2014

Novartis on Tuesday received approval from the Food and Drug Administration for Signifor long-acting release (pasireotide) for injectable suspension, for intramuscular use. 

 

December 11, 2014

Lupin Pharmaceuticals launched the authorized generic version of Celebrex capsules in 50-, 100-, 200- and 400-mg dosage strengths. 

December 10, 2014

Mylan on Wednesday launched its celecoxib capsules in 50-, 100-, 200- and 400-mg dosage strengths. The drug is one of the first available generic versions of Celebrex capsules from Pfizer.

December 10, 2014

Teva Pharmaceutical Industries on Wednesday announced the launch of generic Celebrex (celecoxib) capsules in the United States. The company is offering the capsules in 50-,100-, 200- and 400-mg dosage strengths. 

 

December 9, 2014

Teva Canada, a subsidiary of Teva Pharmaceutical Industries, announced Tuesday that Health Canada has approved its application for the generic version of PrTarceva.